{
    "clinical_study": {
        "@rank": "102402", 
        "acronym": "4EVER UK", 
        "arm_group": {
            "arm_group_label": "RAD001 and Exemestane", 
            "arm_group_type": "Experimental", 
            "description": "Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks."
        }, 
        "brief_summary": {
            "textblock": "Determine the overall response rate (ORR) at 48 weeks to everolimus (RAD001, 10mg daily\n      p.o.) and exemestane (25mg daily p.o.) treatment in postmenopausal women with oestrogen\n      receptor positive breast cancer who have previous experienced recurrence or progression on\n      non-steriodal aromatase inhibitor (NSAI) therapy."
        }, 
        "brief_title": "An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Oestrogen Receptor Positive Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological confirmation of oestrogen receptor positive (ER+) and/or\n             progesterone receptor positive (PgR+), human epidermal growth factor receptor 2\n             (HER2) negative breast cancer.\n\n          -  Availability of archival tumour tissue (the tissue block or slides will be sent to\n             the central laboratory for analysis).\n\n          -  Postmenopausal women. The investigator must confirm postmenopausal status.\n             Postmenopausal status is defined either by:\n\n               -  Age \u2265 55 years and one year or more of amenorrhea\n\n               -  Age < 55 years and one year or more of amenorrhea and postmenopausal levels of\n                  FSH and LH per local institutional standards\n\n               -  Prior hysterectomy and has postmenopausal levels of FSH and LH per local\n                  institutional standards Surgical menopause with bilateral oophorectomy\n\n          -  Disease progression following prior therapy with NSAI, defined as:\n\n               -  Recurrence while on or after completion of an adjuvant treatment including\n                  letrozole or anastrozole, or\n\n               -  Progression while on or following the completion of letrozole or anastrozole\n                  treatment for locally advanced or metastatic breast cancer\n\n        Note: Non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be\n        the last treatment prior to enrollment. Other prior anticancer therapy, e.g. tamoxifen,\n        fulvestrant, exemestane are also allowed. Patients must have recovered to grade 1 or\n        better from any adverse events (except alopecia) related to previous therapy prior to\n        enrollment.\n\n        - Radiological evidence of recurrence or progression on last systemic therapy prior to\n        enrollment.\n\n        Patients must have:\n\n          -  At least one lesion that can be accurately measured or\n\n          -  Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease\n\n             - Adequate bone marrow and coagulation function as shown by:\n\n          -  Absolute neutrophil count (ANC) \u2265 1.5 109/L\n\n          -  Platelets \u2265 100 \u00d7109/L\n\n          -  Hemoglobin (Hb) \u2265 9.0 g/dL\n\n          -  INR \u2264 2 .\n\n             - Adequate liver function as shown by:\n\n          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 ULN\n             (or \u2264 5 if hepatic metastases are present)\n\n          -  Total serum bilirubin \u2264 1.5 \u00d7 ULN (\u2264 3 \u00d7 ULN for patients known to have Gilbert\n             Syndrome)\n\n             - Adequate renal function as shown by:\n\n          -  Serum creatinine \u2264 1.5 \u00d7 ULN - Fasting serum cholesterol \u2264 300 mg/dl or 7.75 mmol/L\n             and fasting triglycerides \u2264 2.5 \u00d7 ULN. In case one or both of these thresholds are\n             exceeded, the patient can only be included after initiation of statin therapy and\n             when the above mentioned values have been achieved\n\n        Exclusion Criteria:\n\n          -  HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ\n             hybridization positive).\n\n          -  Pre-menopausal, pregnant, lactating women.\n\n          -  Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin) or to their\n             excipients.\n\n          -  Known hypersensitivity to exemestane, to the active substance or to any of the\n             excipients.\n\n          -  Patients with  rare hereditary problems of galactose intolerance, Lapp lactase\n             deficiency or glucose galactose malabsorption.\n\n          -  Radiotherapy within four weeks prior to enrollment except in case of localized\n             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can\n             then be completed within two weeks prior to enrollment. Patients must have recovered\n             from radiotherapy toxicities prior to enrollment.\n\n          -  Currently receiving hormone replacement therapy, unless discontinued prior to\n             enrollment.\n\n          -  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids\n             use, at the time of study entry except in cases outlined below:\n\n        Prolonged systemic corticosteroid treatment during study, except for topical applications\n        (e.g. rash),inhaled sprays (e.g. obstructive airways diseases), eye drops or local\n        injections (e.g. intra-articular) should not be given. However:\n\n          -  short duration (<2 weeks) of systemic corticosteroids is allowed (e.g. chronic\n             obstructive pulmonary disease, anti-emetic)\n\n          -  low doses of corticosteroids for brain metastasis treatment is allowed\n\n          -  Patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to\n             pulmonary lymphangitic carcinomatosis and lung metastases or clinically meaningful\n             symptomatic liver metastasis)\n\n          -  Symptomatic brain or other CNS metastases.\n\n          -  Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose\n             warfarin, LMWH and acetylsalicylic acid or equivalent, as long as the INR is 2.0)\n\n          -  Any severe and / or uncontrolled medical conditions such as:\n\n               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial\n                  infarction \u22646 months prior to enrollment, serious uncontrolled cardiac\n                  arrhythmia\n\n               -  Uncontrolled diabetes as defined by fasting serum glucose > 1.5 \u00d7 ULN\n\n               -  Acute and chronic, active infectious disorders (except for Hep B and Hep C\n                  positive patients) and nonmalignant medical illnesses that are uncontrolled or\n                  whose control may be jeopardized by the complications of this study therapy\n\n               -  Impairment of gastrointestinal function or gastrointestinal disease that may\n                  significantly alter the absorption of study drugs (e.g., ulcerative disease,\n                  uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome)\n\n               -  Significant symptomatic deterioration of lung function. If clinically indicated,\n                  pulmonary function tests including measures of predicted lung volumes, DLco, O2\n                  saturation at rest on room air should be considered to exclude restrictive\n                  pulmonary disease, pneumonitis or pulmonary infiltrates.\n\n          -  Patients being treated with drugs recognized as being strong inhibitors or\n             inducers of the isoenzyme CYP3A (rifabutin, rifampicin, clarithromycin, ketoconazole,\n             itroconazole, voriconazole, ritinavir, telithromycin) within the last 5 days prior to\n             enrollment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743560", 
            "org_study_id": "CRAD001YGB11", 
            "secondary_id": "2012-003689-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "RAD001 and Exemestane", 
                "description": "All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.", 
                "intervention_name": "RAD001", 
                "intervention_type": "Drug", 
                "other_name": "Everolimus"
            }, 
            {
                "arm_group_label": "RAD001 and Exemestane", 
                "description": "All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibiotics, Antineoplastic", 
                "Sirolimus", 
                "Exemestane", 
                "Antineoplastic Agents", 
                "Estrogens", 
                "Immunosuppressive Agents", 
                "Everolimus", 
                "Aromatase Inhibitors", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Neoplasms", 
            "Neoplasms", 
            "Breast diseases", 
            "Skin diseases", 
            "Exemastane", 
            "Antibiotics, Antineoplastic", 
            "Everolimus", 
            "Antineoplastic Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Immunosuppressive Agents", 
            "Physiological Effects of Drugs", 
            "Aromatase Inhibitors", 
            "Enzyme Inhibitors", 
            "Molecular Mechanisms of Pharmacological Action"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Epping", 
                        "country": "United Kingdom", 
                        "state": "Essex", 
                        "zip": "CM16 6TN"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ipswich", 
                        "country": "United Kingdom", 
                        "state": "Suffolk", 
                        "zip": "IP4 5PD"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom", 
                        "zip": "CF14 2TL"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denbighshire", 
                        "country": "United Kingdom", 
                        "zip": "LL18 5UJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Kilbride", 
                        "country": "United Kingdom", 
                        "zip": "G75 8RG"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Yorkshire", 
                        "country": "United Kingdom", 
                        "zip": "HU16 5JQ"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "zip": "EH4 2XU"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inverness", 
                        "country": "United Kingdom", 
                        "zip": "IV2 3UJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portsmouth", 
                        "country": "United Kingdom", 
                        "zip": "PO6 3LY"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IV Multicentre, Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane, With Exploratory Epigenetic Marker Analysis", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment success is defined as: The best overall response for each patient is determined from the sequence of investigator overall lesion responses according to RECIST 1.1. To be assigned a best overall response of CR at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best overall response of PR at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.", 
            "measure": "Response rate of everolimus and exemestane treatment in postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Start of treatment to the date of event defined as first documented progression due to any cause up to 24 months"
            }, 
            {
                "description": "Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Start of treatment to date of death due to any cause up to 36 months"
            }, 
            {
                "description": "Descriptive statistics for the changes from baseline to months 3, 6, 9, 12 and follow-up in composite health index and health utility score.", 
                "measure": "Quality of life (EuroQol Standardised Health Outcome Questionnaire EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks and 30 day follow up"
            }, 
            {
                "description": "Descriptive statistics will be used to summarize the individual item and scored sub-scale scores at each scheduled assessment time point. Patients will be included if they completed at least one questionnaire item. Additionally, change from baseline in the domain scores at the time of each assessment will be summarized. Patients with an evaluable baseline score and at least one evaluable post-baseline score during the treatment period will be included in the change from baseline analyses", 
                "measure": "Quality of life (EORTC Quality of Life Questionnaire of cancer patients QLQ-C30)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks and 30 day follow up"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 48 Weeks and will be followed-up for 30 days after end of treatment for safety."
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}